Get all your news in one place.

100’s of premium titles.
One app.

Start reading

Get all your news in one place.

100’s of premium titles. One news app.

Start reading

The Latest Breaking News from Moderna

Moderna study shows immune response in older adults for a combo flu and COVID-19 shot

A combination shot for flu and COVID-19 using messenger RNA generated antibodies in a company-funded study

The Independent UK

Vertex Pharmaceuticals Topples 10% On A Series Of First-Quarter Setbacks

Vertex stock skidded Tuesday on a series of first-quarter setbacks that included light sales, slow uptake for two drugs and a paused study.

Investors Business Daily

Moderna Stock Crumbles As Vaccine Troubles Rattle Its Topline

Moderna stock crumbled Thursday after the biotech company missed sales estimates for its two products, Spikevax and mResvia.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

From COVID to cancer: Why Canada’s RNA vaccine leadership matters more than ever

As the world marks World Immunization Week, attention turns once again to the lifesaving power of vaccines.

The Conversation

FDA scrutiny of Novavax COVID-19 vaccine sparks uncertainty about other shots

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from Novavax

The Independent UK

Moderna Faces Suspension After Offering UK Children £1,500 And Teddy Bears To Join COVID Trials

Moderna, known for its COVID-19 vaccines, has been found guilty of 10 breaches of regulatory code after it marketed its booster jab trials towards children.

International Business Times UK

Novavax says its COVID-19 shot is on track for full FDA approval after delay

Novavax says its closely watched COVID-19 vaccine is on track for full U.S. approval after additional discussions with the Food and Drug Administration

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

What to Expect From Moderna's Q1 2025 Earnings Report

Moderna is scheduled to report its first-quarter results next month, and analysts expect a single-digit earnings growth.

Barchart

What are mRNA vaccines, and how do they work?

mRNA vaccines train the immune system in a similar way to traditional vaccines, but they use a different strategy to get there.

LiveScience

Trump Wants RFK Jr. To 'Go Wild' On Health Care. What This Means For Biotech Stocks.

Robert F. Kennedy Jr. is the new Health Secretary. From fluoride, vaccines and beef tallow, here's how he might "go wild" on biotech stocks.

Investors Business Daily

Analysts at Trump ally Howard Lutnick’s former firm call RFK Jr. ‘an anti-vax, conspiracy theorist with inadequate training’

RFK Jr. was reportedly behind the ouster of FDA’s top vaccine official and said last week that around 10,000 employees will be laid off at the Department of Health and Human Services.

Fortune

Moderna and Novavax shares plunge after key FDA official steps down, citing discord with RFK Jr. who he says 'wishes subservient confirmation of his misinformation and lies'

Massive cuts to personnel and funding within the Department of Health and Human Services presents a headache for vaccine approval and development, analysts say.

Fortune

Stock Market Today: Dow Jones Up As New Trump Stock Rockets; 'Secret' Warren Buffett Stock Clears Entry (Live Coverage)

The Dow Jones rose on the stock market today despite President Trump talking on tariffs. A Warren Buffett stock cleared an entry.

Investors Business Daily

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Biotech stocks were hammered Monday after Peter Marks, a top FDA official, resigned amid a clash with Robert F. Kennedy Jr.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - US

Trump administration at ‘war’ with mRNA technology: scientists alarmed vaccine skeptics could kill research

Public health experts are sounding the alarm over recent move by the NIH to collect information about funding for research into mRNA technology

Barchart

Moderna Stock: Is MRNA Underperforming the Healthcare Sector?

As Moderna has underperformed its broader sector recently, analysts remain cautious about the stock’s prospects.

Reason

Are COVID-19 Vaccines Safe and Effective?

Five years after Donald Trump declared a national COVID-19 emergency, here's what the research says.

MarketBeat

Moderna: 4 Key Reasons the CEO Just Bought $5M in Shares

Moderna stock has fallen to levels not seen in 5 years, but the CEO just spent $5 million buying stock in the open market underscoring his optimism for gains.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

40% Of S&P 500 Stocks Fall Into Dreaded Trump Bear Market

Not sure when President Trump's tariff strategy will push the S&P 500 into a bear market? It's already here for 40% of the S&P 500.

Investors Business Daily

Why Moderna Stock Has Surged 15% This Week Despite Mixed News

Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market.

Investors Business Daily

Moderna Stock Slumps 7% On A Surprise Twist In The RFK Jr. Saga

Moderna stock toppled Thursday on reports the Trump administration is considering pulling bird flu vaccine funding.

Barchart

Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now?

A promising pipeline provides long-term potential for Moderna.

MarketBeat

Moderna: A Generational Opportunity for Investors in 2025

Moderna had a weak quarter but reaffirmed guidance, expecting three new product approvals in 2025 and as many as ten more within three years.

Investors Business Daily

Moderna Stock Reverses As CEO Stephane Bancel Deflects Concerns Over RFK Jr.

Chief Executive Stephane Bancel says Moderna will work with the Trump administration. Moderna stock rose in midday trades.

Barchart

Do Wall Street Analysts Like Moderna Stock?

Moderna has continued to underperform the broader market over the past year and analysts remain cautious about the stock’s prospects.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

SP Global Market Intelligence

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.